Inhibitors of lysine specific demethylase-1

Patent metadata

Field	Value
Publication number	US-10864202-B2
Application number	US-201916705135-A
Country	US
Kind code	B2
Filing date	Dec 5, 2019
Priority date	Sep 5, 2014
Publication date	Dec 15, 2020
Grant date	Dec 15, 2020

Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

First claim

We claim:

1. A compound having the structure of Formula (IV), or a pharmaceutically acceptable salt thereof,

wherein,
X and Y are each independently chosen from C—H, C—F, C—CH 3 , or N;
Z is chosen -G, —CH 2 -G, —CH 2 —CH 2 -G, —N(R′)-G, —N(R′)—CH 2 -G, —O-G, —O—CH 2 -G, or —C(O)N(R 2 )(R 3 );
X 1 , X 2 , and X 3 are any one of the following;
(i) X 1 is N; X 2 is N; and X 3 is C—R 4 ;
(ii) X 1 is N; X 2 is C—R 4 ; and X 3 is C—R 4 ;
(iii) X 1 is C—R 4 ; X 2 is N; and X 3 is N;
(iv) X 1 is C—R 4 ; X 2 is C—R 4 ; and X 3 is N;
(v) X 1 is C—R 4 ; X 2 is N; and X 3 is C—R 4 ;
(vi) X 1 is N; X 2 is N; and X 3 is N;

G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
R 1 is hydrogen or alkyl;
R 2 and R 3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R 2 and R 3 join to form an N-linked heterocyclyl ring system;
R 4 is hydrogen, halogen, C1-C3 alkyl or C1-C3 alkoxy; and
R is aryl, heteroaryl, alkynyl, or cycloalkylalkynylene.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R is aryl or heteroaryl.

3. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Formula (IV) is Formula (IVa):

4. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Formula (IV) is Formula (IVb):

5. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Formula (IV) is Formula (IVd):

6. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Formula (IV) is Formula (IVe):

7. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Formula (IV) is Formula (IVf):

8. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Formula (IV) is Formula (IVg):

9. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein X is C—H.

10. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein X is C—F.

11. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein X is C—CH 3 .

12. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein X is N.

13. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Y is C—H.

14. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Y is C—F.

15. The compound of claim 1 or pharmaceutically acceptable salt thereof, wherein Y is C—CH 3 .

16. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Y is N.

17. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein X is C—H and Y is C—H.

18. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of:
(a) —O—CH 2 -G;
(b) —O-G;
(c) —N(R′)—CH 2 -G;
(d) —N(R′)-G;
(e) —CH 2 —CH 2 -G;
(f) —CH 2 -G;
(g) -G; and
(h) —C(O)N(R 2 )(R 3 ).

19. The compound of claim 18 , or pharmaceutically acceptable salt thereof, wherein:
(a) R 2 and R 3 are independently selected from hydrogen or alkyl; or
(b) R 2 and R 3 are independently selected from heterocyclyl or heterocyclylalkyl; or
(c) R 2 and R 3 join to form an N-linked heterocyclyl ring system.

20. The compound of claim 18 , or pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or alkyl.

21. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen or C1-C3 alkoxy.

22. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl or a nitrogen-containing heterocyclyl.

23. The compound of claim 22 , or pharmaceutically acceptable salt thereof, wherein the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl.

24. The compound of claim 22 , or pharmaceutically acceptable salt thereof, wherein the heterocyclyl is chosen from:

25. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of:
(a) heteroaryl;
(b) a monocyclic nitrogen-containing heteroaryl;
(c) a bicyclic nitrogen-containing heteroaryl; and
(d) aryl.

26. The compound of claim 25 , or pharmaceutically acceptable salt thereof, wherein R is chosen from:

27. The compound of claim 25 , or pharmaceutically acceptable salt thereof, wherein the aryl is an optionally substituted phenyl group.

28. The compound of claim 27 , or pharmaceutically acceptable salt thereof, wherein the optionally substituted phenyl group is chosen from 4-methylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, 4-(methylsulfonyl)phenyl, or 4-trifluoromethylphenyl.

29. The compound of claim 27 , or pharmaceutically acceptable salt thereof, wherein the optionally substituted phenyl group is chosen from 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, or 3-chloro-4-methoxyphenyl.

30. A pharmaceutical composition comprising a compound of Formula (IV) as described in claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

31. A method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (IV) as described in claim 1 .

32. A method of treating acute myeloid leukemia, breast or prostate cancer in a patient in need thereof comprising administering a pharmaceutical composition comprising a compound of Formula (IV) as described in claim 1 .

33. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein the compound is selected from:
4-[5-(4-methylphenyl)-2-{[(3S)-pyrrolidin-3-ylmethyl]amino}pyrimidin-4-yl]benzonitrile;
4-[5-(4-fluorophenyl)-2-{[(3S)-pyrrolidin-3-ylmethyl]amino}pyrimidin-4-yl]benzonitrile;
4-[5-(4-chlorophenyl)-2-{[(3S)-pyrrolidin-3-ylmethyl]amino}pyrimidin-4-yl]benzonitrile;
4-[5-(4-methylphenyl)-2-[(3R)-pyrrolidin-3-ylmethoxy]pyrimidin-4-yl]benzonitrile;
4-{2-[(3aR,6aS)-octahydropyrrolo[3,4-c]pyrrol-2-yl]-5-(4-methylphenyl)pyrimidin-4-yl}benzonitrile;
4-[5-(4-methylphenyl)-2-{octahydro-1H-pyrrolo[3,4-c]pyridin-5-yl}pyrimidin-4-yl]benzonitrile;
4-{2-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-6-yl]-5-(4-methylphenyl)pyrimidin-4-yl}benzonitrile;
4-{2-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-6-yl]-5-(4-fluorophenyl)pyrimidin-4-

Assignees

• Celgene Quanticel Res Inc

Inventors

• Chen Young K
• Kanouni Toufike
• Stafford Jeffrey Alan
• Veal James Marvin

Classifications

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D498/08

  Bridged systems · CPC title

• C07D471/10

  Spiro-condensed systems · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title